Next Article in Journal
Cultivation of Chlorella vulgaris and Arthrospira platensis with Recovered Phosphorus from Wastewater by Means of Zeolite Sorption
Next Article in Special Issue
MiR-25 Protects Cardiomyocytes against Oxidative Damage by Targeting the Mitochondrial Calcium Uniporter
Previous Article in Journal
Phosphoproteomic Analysis of the Highly-Metastatic Hepatocellular Carcinoma Cell Line, MHCC97-H
Previous Article in Special Issue
Heart Failure and Atrial Fibrillation: From Basic Science to Clinical Practice
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(2), 4226-4249; doi:10.3390/ijms16024226

Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure

1
Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School, São Paulo 05403-000, SP, Brazil
2
Department of Physiological Sciences, Federal University of Espírito Santo, Vitoria 29043-900, ES, Brazil
*
Author to whom correspondence should be addressed.
Academic Editor: Yi-Han Chen
Received: 5 January 2014 / Revised: 5 February 2015 / Accepted: 9 February 2015 / Published: 16 February 2015
(This article belongs to the Special Issue Pathogenesis of Cardiac Arrhythmias and Heart Failure)
View Full-Text   |   Download PDF [1532 KB, uploaded 16 February 2015]   |  

Abstract

Dipeptidyl peptidase IV (DPPIV) is a widely expressed multifunctional serine peptidase that exists as a membrane-anchored cell surface protein or in a soluble form in the plasma and other body fluids. Numerous substrates are cleaved at the penultimate amino acid by DPPIV, including glucagon-like peptide-1 (GLP-1), brain natriuretic peptide (BNP) and stromal cell-derived factor-1 (SDF-α), all of which play important roles in the cardiovascular system. In this regard, recent reports have documented that circulating DPPIV activity correlates with poorer cardiovascular outcomes in human and experimental heart failure (HF). Moreover, emerging evidence indicates that DPPIV inhibitors exert cardioprotective and renoprotective actions in a variety of experimental models of cardiac dysfunction. On the other hand, conflicting results have been found when translating these promising findings from preclinical animal models to clinical therapy. In this review, we discuss how DPPIV might be involved in the cardio-renal axis in HF. In addition, the potential role for DPPIV inhibitors in ameliorating heart disease is revised, focusing on the effects of the main DPPIV substrates on cardiac remodeling and renal handling of salt and water. View Full-Text
Keywords: glucagon-like peptide-1; brain natriuretic peptide; stromal cell-derived factor-1; renal function; cardiac dysfunction; natriuresis; cardioprotection; renoprotection glucagon-like peptide-1; brain natriuretic peptide; stromal cell-derived factor-1; renal function; cardiac dysfunction; natriuresis; cardioprotection; renoprotection
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Salles, T.A.; dos Santos, L.; Barauna, V.G.; Girardi, A.C.C. Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure. Int. J. Mol. Sci. 2015, 16, 4226-4249.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top